Hansa Biopharma — Februar 2023
-
Hansa Biopharma: Update ahead of 2023 – Gradual progress ahead
Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months.
-
We make a slight negative revision after the recent Q4 result, and the most significant change is the number of shares relating to funding protecting the equity levels.
Our Base Case is SEK 170 (410) with a Bull Case of SEK 400 (600) and a Bear Case of SEK 45 (175). -
-
Hansa Biopharma Automatisk teknisk analys. Medellång sikt, 14 feb 2023 (for dem som er til TA):
Hansa Biopharma - teknisk analys av aktien - Dagens industri
Utförlig grafisk information om Hansa Biopharma historiska utveckling som ger en hint om aktiens framtida utveckling.
Dagens industri (www.di.se)
(Dagens industri)
-
"Elisabeth Sonnesson, Global Franchise Lead Autoimmunity presented last week at Erik Pensers Healthcare Day focusing on autoimmune diseases. A very insightful presentation on the autoimmune space and the programs Hansa is currently investigating" https://proinvestor.com/boards/110967
Aps ja du har ret alle stigninger neutraliseres hurtigt øv
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind